Search

Your search keyword '"Giugliano, E"' showing total 3 results
Start Over Author "Giugliano, E" Publication Type Electronic Resources
3 results on '"Giugliano, E"'

1. miR-15a targets the HSP90 co-chaperone Morgana in chronic myeloid leukemia

Author

Poggio, P, Rocca, S, Fusella, F, Ferretti, R, Ala, U, D'Anna, F, Giugliano, E, Panuzzo, C, Fontana, D, Palumbo, V, Carrà, G, Taverna, D, Gambacorti-Passerini, C, Saglio, G, Fava, C, Piazza, R, Morotti, A, Orso, F, Brancaccio, M, Poggio, Pietro, Rocca, Stefania, Fusella, Federica, Ferretti, Roberta, Ala, Ugo, D'Anna, Flora, Giugliano, Emilia, Panuzzo, Cristina, Fontana, Diletta, Palumbo, Valeria, Carrà, Giovanna, Taverna, Daniela, Gambacorti-Passerini, Carlo, Saglio, Giuseppe, Fava, Carmen, Piazza, Rocco, Morotti, Alessandro, Orso, Francesca, Brancaccio, Mara, Poggio, P, Rocca, S, Fusella, F, Ferretti, R, Ala, U, D'Anna, F, Giugliano, E, Panuzzo, C, Fontana, D, Palumbo, V, Carrà, G, Taverna, D, Gambacorti-Passerini, C, Saglio, G, Fava, C, Piazza, R, Morotti, A, Orso, F, Brancaccio, M, Poggio, Pietro, Rocca, Stefania, Fusella, Federica, Ferretti, Roberta, Ala, Ugo, D'Anna, Flora, Giugliano, Emilia, Panuzzo, Cristina, Fontana, Diletta, Palumbo, Valeria, Carrà, Giovanna, Taverna, Daniela, Gambacorti-Passerini, Carlo, Saglio, Giuseppe, Fava, Carmen, Piazza, Rocco, Morotti, Alessandro, Orso, Francesca, and Brancaccio, Mara

Abstract

Morgana is a ubiquitous HSP90 co-chaperone protein coded by the CHORDC1 gene. Morgana heterozygous mice develop with age a myeloid malignancy resembling human atypical myeloid leukemia (aCML), now renamed MDS/MPN with neutrophilia. Patients affected by this pathology exhibit low Morgana levels in the bone marrow (BM), suggesting that Morgana downregulation plays a causative role in the human malignancy. A decrease in Morgana expression levels is also evident in the BM of a subgroup of Philadelphia-positive (Ph+) chronic myeloid leukemia (CML) patients showing resistance or an incomplete response to imatinib. Despite the relevance of these data, the mechanism through which Morgana expression is downregulated in patients’ bone marrow remains unclear. In this study, we investigated the possibility that Morgana expression is regulated by miRNAs and we demonstrated that Morgana is under the control of four miRNAs (miR-15a/b and miR-26a/b) and that miR-15a may account for Morgana downregulation in CML patients.

Published
2024

2. Clonal hematopoiesis by DNMT3A mutations as a common finding in idiopathic splanchnic vein thrombosis

Author

Carrà, G, Giugliano, E, Camerlo, S, Rosati, G, Branca, E, Maffeo, B, Russo, I, Piazza, R, Cilloni, D, Morotti, A, Carrà, Giovanna, Giugliano, Emilia, Camerlo, Sofia, Rosati, Giorgio, Branca, Enrica, Maffeo, Beatrice, Russo, Isabella, Piazza, Rocco, Cilloni, Daniela, Morotti, Alessandro, Carrà, G, Giugliano, E, Camerlo, S, Rosati, G, Branca, E, Maffeo, B, Russo, I, Piazza, R, Cilloni, D, Morotti, A, Carrà, Giovanna, Giugliano, Emilia, Camerlo, Sofia, Rosati, Giorgio, Branca, Enrica, Maffeo, Beatrice, Russo, Isabella, Piazza, Rocco, Cilloni, Daniela, and Morotti, Alessandro

Published
2023

3. Morgana acts as an oncosuppressor in chronic myeloid leukemia

Author

Di Savino, A, Panuzzo, C, Rocca, S, Familiari, U, Piazza, R, Crivellaro, S, Carrà, G, Ferretti, R, Fusella, F, Giugliano, E, Camporeale, A, DE FRANCO, I, Miniscalco, B, Cutrin, J, Turco, E, Silengo, L, Hirsch, E, Rege Cambrin, G, GAMBACORTI PASSERINI, C, Pandolfi, P, Papotti, M, Saglio, G, Tarone, G, Morotti, A, Brancaccio, M, Brancaccio, M., PIAZZA, ROCCO GIOVANNI, DE FRANCO, IRENE, GAMBACORTI PASSERINI, CARLO, Di Savino, A, Panuzzo, C, Rocca, S, Familiari, U, Piazza, R, Crivellaro, S, Carrà, G, Ferretti, R, Fusella, F, Giugliano, E, Camporeale, A, DE FRANCO, I, Miniscalco, B, Cutrin, J, Turco, E, Silengo, L, Hirsch, E, Rege Cambrin, G, GAMBACORTI PASSERINI, C, Pandolfi, P, Papotti, M, Saglio, G, Tarone, G, Morotti, A, Brancaccio, M, Brancaccio, M., PIAZZA, ROCCO GIOVANNI, DE FRANCO, IRENE, and GAMBACORTI PASSERINI, CARLO

Abstract

We recently described morgana as an essential protein able to regulate centrosome duplication and genomic stability, by inhibiting ROCK. Here we show that morgana+/- mice spontaneously develop a lethal myeloproliferative disease resembling human atypical chronic myeloid leukemia (aCML), preceded by ROCK hyperactivation, centrosome amplification, and cytogenetic abnormalities in the bone marrow (BM). Moreover,we found that morgana is underexpressed in the BM of patients affected by atypical CML, a disorder of poorly understood molecular basis, characterized by nonrecurrent cytogenetic abnormalities. Morgana is also underexpressed in the BM of a portion of patients affected by Philadelphia-positive CML (Ph+ CML) caused by the BCR-ABL oncogene, and in this condition, morgana underexpression predicts a worse response to imatinib, the standard treatment for Ph+ CML. Thus,morgana acts as an oncosuppressor with different modalities: (1) Morgana underexpression induces centrosome amplification and cytogenetic abnormalities, and (2) in Ph+ CML, it synergizes with BCR-ABL signaling, reducing the efficacy of imatinib treatment. Importantly, ROCK inhibition in the BM of patients underexpressing morgana restored the efficacy of imatinib to induce apoptosis, suggesting that ROCK inhibitors, combined with imatinib treatment, can overcome suboptimal responses in patients in which morgana is underexpressed.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results